Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
72 hedge funds and large institutions have $273M invested in Albireo Pharma Inc in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 27 increasing their positions, 20 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
40% more capital invested
Capital invested by funds: $195M → $273M (+$78.6M)
35% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 20
6% more funds holding
Funds holding: 68 → 72 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
53% less call options, than puts
Call options by funds: $193K | Put options by funds: $412K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.57M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.59M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$1.3M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.17M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$682K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.64M |
| 2 |
Renaissance Technologies
New York
|
-$358K |
| 3 |
Morgan Stanley
New York
|
-$332K |
| 4 |
BlackRock
New York
|
-$304K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$236K |
ALBO Hedge Fund Activity: Q1 2019 in Review
72 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q1 2019, worth a combined $273M — up 40% from $195M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ALBO positions and 1 closed out — a net gain of 4 holders — while 27 added to existing stakes and 20 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $4.57M. The largest seller was Fidelity Investments, cutting an estimated $1.64M.
- 72 institutional investors held Albireo Pharma Inc (ALBO) as of Q1 2019, up from 68 in Q4 2018.
- Funds reported $273M of Albireo Pharma Inc stock for Q1 2019, up 40% quarter-over-quarter.
- 5 funds opened new Albireo Pharma Inc positions in Q1 2019 and 1 closed out, a net change of +4 holders.
- The largest Albireo Pharma Inc buyer in Q1 2019 was Point72 Asset Management, an estimated $4.57M added.
- The largest Albireo Pharma Inc seller in Q1 2019 was Fidelity Investments, an estimated $1.64M sold.
Based on aggregated 13F filings for Q1 2019.